Resected pancreatic adenocarcinoma: An Asian institution's experience.

ABSTRACT:

Background

Pancreatic adenocarcinoma (PDAC) is highly lethal. Surgery offers the only chance of cure, but 5-year overall survival (OS) after surgical resection and adjuvant therapy remains dismal. Adjuvant trials were mostly conducted in the West enrolling fit patients. Applicability to a general population, especially Asia has not been described adequately.

Aim

We aimed to evaluate the clinical outcomes, prognostic factors of survival, pattern, and timing of recurrence after curative resection in an Asian institution.

Methods and results

The clinicopathologic and survival outcomes of 165 PDAC patients who underwent curative resection between 1998 and 2013 were reviewed retrospectively. Median age at surgery was 62.0 years. 55.2% were male, and 73.3% had tumors involv

SUBMITTER: Ng KYY 

PROVIDER: S-EPMC8551988 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature